Cellebrite DI Ltd. (NASDAQ:CLBT) Shares Sold by Clal Insurance Enterprises Holdings Ltd

Clal Insurance Enterprises Holdings Ltd trimmed its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 11.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,496,109 shares of the company's stock after selling 469,838 shares during the period. Clal Insurance Enterprises Holdings Ltd owned 1.70% of Cellebrite DI worth $77,019,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Quarry LP acquired a new position in Cellebrite DI in the 3rd quarter valued at about $27,000. Advisors Asset Management Inc. increased its holdings in Cellebrite DI by 130.5% in the third quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company's stock valued at $52,000 after buying an additional 1,742 shares in the last quarter. R Squared Ltd acquired a new position in Cellebrite DI during the fourth quarter worth $100,000. Venturi Wealth Management LLC raised its stake in shares of Cellebrite DI by 28.6% during the 3rd quarter. Venturi Wealth Management LLC now owns 9,000 shares of the company's stock worth $152,000 after buying an additional 2,000 shares during the last quarter. Finally, MQS Management LLC purchased a new stake in shares of Cellebrite DI in the third quarter valued at about $294,000. 45.88% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on CLBT. Lake Street Capital raised their price target on Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a research report on Friday, February 14th. JPMorgan Chase & Co. boosted their target price on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. Craig Hallum raised their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $28.00 price objective on shares of Cellebrite DI in a research report on Friday, February 14th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Cellebrite DI presently has an average rating of "Buy" and an average target price of $23.43.

Remove Ads

Cellebrite DI Stock Up 1.7 %

Shares of CLBT stock traded up $0.31 during trading hours on Wednesday, hitting $18.34. 741,530 shares of the company were exchanged, compared to its average volume of 1,107,070. The firm has a fifty day moving average of $22.14 and a 200 day moving average of $19.69. Cellebrite DI Ltd. has a 1 year low of $10.25 and a 1 year high of $26.30. The firm has a market cap of $3.78 billion, a PE ratio of -13.19, a PEG ratio of 4.27 and a beta of 1.47.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. Analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.